Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Clin Cancer Res. 2009 May 5;15(10):3617–3623. doi: 10.1158/1078-0432.CCR-08-3071

Table 3.

Plasma pharmacokinetic parameters of enzastaurin and LY326020 for Group B patients (non-EIAED)

Parameter 1,000 mg daily
500 mg twice daily
Patient 1 Patient 2 Patient 2
Enzastaurin
 Cmax,ss (nmol/L) 3,012 2,730 4,093
 Tmax (h) 4.00 2.00 4.00
 Cav,ss (nmol/L) 1,340 1,350 3,050
 CL/F (L/h) 60 60 27
LY326020
 Cmax,ss (nmol/L) 1,867 808 870
 Tmax (h) 6.00 4.00 6.00
 Cav,ss (nmol/L) 1,640 697 819
 MR (ratio) 1.22 0.516 0.269
Total Analyte
 Cmax,ss (nmol/L) 4,832 3,873 5,860
 Tmax (h) 4.00 2.00 4.00
 Cav,ss (nmol/L) 3,150 2,380 4,730

NOTE: Of five patients enrolled on this arm of the study, pharmacokinetic data are partially available for two patients.